BACKGROUND: It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid leukemia in chronic phase who are given nilotinib or dasatinib therapy after treatment failure with imatinib. DESIGN AND METHODS: To address this issue we compared the survival of 104 patients in whom first-line therapy with imatinib failed and who were then treated with second-generation tyrosine kinase inhibitors with the outcome of 246 patients in whom interferon-α therapy failed and who did not receive tyrosine kinase inhibitor therapy. RESULTS: Patients treated with second-generation tyrosine kinase inhibitors had longer overall survival than the interferon controls (adjusted relative risk= 0.28, P=0.0001). However this survival advantage was limited to the 64.4% of patients in whom imatinib failed but who achieved complete cytogenetic response with the subsequent tyrosine kinase inhibitor (adjusted relative risk =0.05, P=0.003), whereas the 35.6% of patients who failed to achieve complete cytogenetic response on the second or third inhibitor had similar overall survival to that of the controls (adjusted relative risk=0.76, P=0.65). CONCLUSIONS: Patients in whom imatinib treatment fails who receive sequential therapy with second-generation tyrosine kinase inhibitors have an enormous advantage in survival over controls (palliative therapy); this advantage is, however, limited to the majority of the patients who achieve a complete cytogenetic response.
RCT Entities:
BACKGROUND: It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid leukemia in chronic phase who are given nilotinib or dasatinib therapy after treatment failure with imatinib. DESIGN AND METHODS: To address this issue we compared the survival of 104 patients in whom first-line therapy with imatinib failed and who were then treated with second-generation tyrosine kinase inhibitors with the outcome of 246 patients in whom interferon-α therapy failed and who did not receive tyrosine kinase inhibitor therapy. RESULTS:Patients treated with second-generation tyrosine kinase inhibitors had longer overall survival than the interferon controls (adjusted relative risk= 0.28, P=0.0001). However this survival advantage was limited to the 64.4% of patients in whom imatinib failed but who achieved complete cytogenetic response with the subsequent tyrosine kinase inhibitor (adjusted relative risk =0.05, P=0.003), whereas the 35.6% of patients who failed to achieve complete cytogenetic response on the second or third inhibitor had similar overall survival to that of the controls (adjusted relative risk=0.76, P=0.65). CONCLUSIONS:Patients in whom imatinib treatment fails who receive sequential therapy with second-generation tyrosine kinase inhibitors have an enormous advantage in survival over controls (palliative therapy); this advantage is, however, limited to the majority of the patients who achieve a complete cytogenetic response.
Authors: Neil P Shah; Dong-Wook Kim; Hagop Kantarjian; Philippe Rousselot; Pedro Enrique Dorlhiac Llacer; Alicia Enrico; Jorge Vela-Ojeda; Richard T Silver; Hanna Jean Khoury; Martin C Müller; Alexandre Lambert; Yousif Matloub; Andreas Hochhaus Journal: Haematologica Date: 2010-02 Impact factor: 9.941
Authors: Amr R Ibrahim; Christos Paliompeis; Marco Bua; Dragana Milojkovic; Richard Szydlo; Jamshid S Khorashad; Letizia Foroni; Alistair Reid; Hugues de Lavallade; Katayoun Rezvani; Francesco Dazzi; Jane F Apperley; John M Goldman; David Marin Journal: Blood Date: 2010-09-10 Impact factor: 22.113
Authors: Hugues de Lavallade; Jane F Apperley; Jamshid S Khorashad; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin Journal: J Clin Oncol Date: 2008-06-02 Impact factor: 44.544
Authors: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre Journal: Blood Date: 2010-11-22 Impact factor: 22.113
Authors: Dragana Milojkovic; Emma Nicholson; Jane F Apperley; Tessa L Holyoake; Pat Shepherd; Mark W Drummond; Richard Szydlo; Marco Bua; Letizia Foroni; Alistair Reid; Jamshid S Khorashad; Hugues de Lavallade; Katy Rezvani; Christos Paliompeis; John M Goldman; David Marin Journal: Haematologica Date: 2009-10-14 Impact factor: 9.941
Authors: Hagop Kantarjian; Francis Giles; Lydia Wunderle; Kapil Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann Journal: N Engl J Med Date: 2006-06-15 Impact factor: 91.245
Authors: L J Crawford; E T Chan; M Aujay; T L Holyoake; J V Melo; H G Jorgensen; S Suresh; B Walker; A E Irvine Journal: Oncogenesis Date: 2014-03-03 Impact factor: 7.485